Series C brings in $100mm for Revolution Medicines

15:40 EDT 10 Jul 2019 | Elsevier Business Intelligence

Cancer drug developer Revolution Medicines Inc. raised $100mm through its Series C round. Boxer Capital (of Tavistock) led an...

Original Article: Series C brings in $100mm for Revolution Medicines

More From BioPortfolio on "Series C brings in $100mm for Revolution Medicines"